物质使用障碍的次低频神经反馈治疗：一项随机对照试验。
Infralow neurofeedback in the treatment of substance use disorders: a randomized controlled trial.
机构信息
From the Addiction Unit, Sørlandet Hospital, Kristiansand, Norway (Gabrielsen, Clausen, Vederhus); the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway (Clausen); the Department of Psychosocial Health, University of Agder, Grimstad, Norway (Haugland); the Norwegian University of Science and Technology, Trondheim, Norway (Hollup)
From the Addiction Unit, Sørlandet Hospital, Kristiansand, Norway (Gabrielsen, Clausen, Vederhus); the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway (Clausen); the Department of Psychosocial Health, University of Agder, Grimstad, Norway (Haugland); the Norwegian University of Science and Technology, Trondheim, Norway (Hollup).
出版信息
J Psychiatry Neurosci. 2022 Jun 15;47(3):E222-E229. doi: 10.1503/jpn.210202. Print 2022 May-Jun.
BACKGROUND
Infralow neurofeedback (ILF-NF) was recently developed as a subtype of traditional, frequency-based neurofeedback that targets cerebral rhythmic activity below 0.5 Hz and improves brain self-regulation. The efficacy of ILF-NF in the treatment of substance use disorder has not yet been evaluated, but clinical evidence suggests that it may prevent relapse by improving functioning in various life domains. The current study aimed to fill this research gap and extend empirical evidence related to this issue.
METHODS
Ninety-three patients with substance use disorders at an outpatient unit in Norway were randomized to receive 20 sessions (30 minutes each) of ILF-NF training combined with treatment as usual (TAU), or TAU alone. The primary outcome was quality of life post-treatment as an overall measure of functioning. We analyzed between-group differences using Student tests.
RESULTS
We found no significant differences in quality of life between groups. We found similar nonsignificant results for most of the secondary outcome measures, including drug use, sleep, anxiety and depression. Compared to TAU, the ILF-NF + TAU group reported significantly lower restlessness scores post-treatment (mean difference -1.8, 95 % confidence interval -3.1 to -0.5; = 0.006). This study was limited by broad inclusion criteria and a lack of placebo control (sham neurofeedback treatment).
CONCLUSION
ILF-NF offered limited additional benefit when combined with TAU, except in the area of restlessness. Future studies could further investigate the relationship between ILF-NF, restlessness and substance use in targeted subpopulations to illuminate relapse mechanisms.
CLINICAL TRIAL REGISTRATION
ClinicalTrials.gov: NCT03356210.
背景
最近开发了一种低频神经反馈（ILF-NF），作为传统基于频率的神经反馈的一个亚型，其目标是大脑低于 0.5 Hz 的节律性活动，并改善大脑的自我调节。ILF-NF 在治疗物质使用障碍方面的疗效尚未得到评估，但临床证据表明，它可能通过改善各种生活领域的功能来预防复发。本研究旨在填补这一研究空白，并为这一问题提供更多的实证证据。
方法
挪威一家门诊单位的 93 名物质使用障碍患者被随机分为两组，分别接受 20 次（每次 30 分钟）ILF-NF 训练联合常规治疗（TAU），或仅接受 TAU。主要结局是治疗后作为功能整体测量的生活质量。我们使用学生 t 检验分析组间差异。
结果
我们没有发现两组之间在生活质量上有显著差异。我们发现大多数次要结局测量指标也没有显著差异，包括药物使用、睡眠、焦虑和抑郁。与 TAU 相比，ILF-NF + TAU 组在治疗后报告的不安评分显著降低（平均差值 -1.8，95%置信区间 -3.1 至 -0.5； = 0.006）。本研究受到广泛纳入标准和缺乏安慰剂对照（假神经反馈治疗）的限制。
结论
除了在不安方面，ILF-NF 与 TAU 联合使用时提供的额外益处有限。未来的研究可以进一步调查 ILF-NF、不安和物质使用之间的关系，以阐明复发机制。
临床试验注册
ClinicalTrials.gov：NCT03356210。
Zotero 插件